LakeShore Biopharma still sees FY25 revenue up in double digits year-over-year

Sees FY24 revenue RMB350M-RMB380M, representing growth of 28%-39% from RMB273.1M revenue in FY24. CEO Xu Wang commented, “By reaffirming our full-year guidance, we are expressing belief in our ability to maintain our positive momentum and achieve our financial and operational objectives. With our new management team in place, Lakeshore Biopharma has not only maintained smooth operations, but also secured second position in China’s Rabies vaccine market. Armed with a robust business model and a strong pipeline, we have consistently demonstrated our capacity to execute our core strategies effectively. Building on this solid foundation, we are actively forging long-term strategic partnerships through licensing, promotions, and other collaborative agreements. As we progress through FY25 with a clear plan to enhance sustainability, efficiency, and innovation, I am confident that our team will deliver success across these areas, creating enduring value for our company and our shareholders.”